A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer

A new Oncology Advance study finds benefits to stop-and-go chemotherapy in treating metastatic gastric cancer. Researchers found that continuous treatment boosted progression-free survival (the amount of time patients lived with no worsening of disease), but there was no difference between the two treatment regimens in overall survival (how long they lived), and quality of life favored the stop and go treatment protocol.